Future doping oral EPO booster drug appears to work.

Massive increases in natural erythropoietin (EPO) production occurred in dialysis patients as well as healthy volunteers given an investigational oral drug that promotes release of the red blood cell growth factor, according to results of a small trial.

The phase I trial, conducted among 12 dialysis patients and six healthy individuals, found that plasma EPO levels increased from 13- to 31-fold following a single dose of FG-2216, an orally active prolyl-hydroxylase inhibitor.

No comments:

Post a Comment